ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

160
Analysis
Health CareChina
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
Refresh
13 Aug 2023 22:18

The Brand Spanking New Extra Spiffy 🦄H/A-Share Discount/Premium Weekly (As of 11 Aug 2023)

Quiddity's New & Improved And Really Quite Spiffy H/A Discount Monitor. All the H/A Pairs, universe & sector metrics, with interactive tables and...

Logo
636 Views
Share
07 Nov 2023 08:55

CanSino Biologics (6185.HK/688185.CH) 23Q3 - Some Positive Business Progress Worth the Attention

CanSino’s performance/valuation is at low point, but MCV4's sales exceeded expectation.On 2023 low base, growth in 2024 is worth looking forward...

Logo
287 Views
Share
09 Jun 2021 09:15

CanSino Biologics (688185.CH/6185.HK) - Time for Corner Overtaking?

The inhaled COVID-19 vaccine of CanSino is applying for emergency use in China,which worth the attention of investors.The article analyzed the...

Logo
240 Views
Share
26 Mar 2024 08:55

Pre-IPO Beijing Health Guard Biotechnology - The Story of the HPV Vaccine Is Not as Good as Imagined

The real China’s HPV vaccine market could be smaller-than-expected.After being included in National Immunization Program, vaccine business will be...

Logo
409 Views
Share
13 Aug 2023 09:25

China Healthcare Weekly (Aug11)-Anti-Corruption Update, Increase A-Share Shareholder Return, CanSino

We updated the impact of anti-corruption in different sectors.Healthcare company need to increase share buyback/dividend to improve shareholder'...

Logo
326 Views
Share
x